Cancer, OtorhinolaryngealRADEFILACNCT06604494
Rehabilitation Improved by Early Detection of Fisyulas Post (Pharyngo) -Total Laryngectomy by Cytokine Measurement on Drainage Fluid on the Second Post-Operative Day
A study testing early feeding resumption and late feeding resumption in people with Cancer, Otorhinolaryngeal, run by University Hospital, Clermont-Ferrand at 7 sites in France.
Trial summary
Post-pharyngo-laryngectomy fistula is a frequent surgical complication, resulting in delayed patient management and reduced quality of life. A recent study has shown that the appearance of a fistula can be detected early by measuring cytokines (particularly IL10) in postoperative drainage fluids. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer, Otorhinolaryngeal
- What is being tested?
- early feeding resumption and late feeding resumption
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 250 participants
- Where
- 7 sitesFrance
- Study dates
- 12 Feb 2025to May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patient with cancer requiring a total laryngectomy or pharyngolaryngectomy scheduled after multidisciplinary consultation.
- Holder of a social security scheme
Who cannot join
- Pregnant and breastfeeding women Persons under curatorship, guardianship, legal protection or deprived of liberty Any medical condition deemed by the investigator to be incompatible with the study. Refusal to participate. Body mass index less than 18.5 kg/ m2
- -
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
France7 sites, 7 recruiting
- Recruiting
CHU de Clermont-Ferrand
Clermont-Ferrand
Lise Laclautre
Nicolas Saroul
- Not yet recruiting
CHU de Grenoble
Grenoble
Lise Laclautre
Fabre Christol
- Not yet recruiting
CH Emile Roux
Le Puy-en-Velay
Lise Laclautre
Marc Durand
- Not yet recruiting
HCL Hôpital Croix Rousse
Lyon
Lise Laclautre
Philippe CERUSE
- Not yet recruiting
CHU de Saint-Etienne
Saint-Etienne
Lise Laclautre
Yann Lelonge
- Not yet recruiting
CH de Valence
Valence
Lise Laclautre
Guillaume Buiret
- Not yet recruiting
Institut Gustave Roussy
Villejuif
Lise Laclautre
Ingrid Breuskin
About this study
Post-pharyngo-laryngectomy fistula is a frequent surgical complication, resulting in delayed patient management and reduced quality of life. A recent study has shown that the appearance of a fistula can be detected early by measuring cytokines (particularly IL10) in postoperative drainage fluids. Resumption of feeding following this surgery varies between postoperative day 5 and postoperative day 15, depending on the team\'s habits. Early refeeding reduces the length of hospital stay and improves patients\' quality of life. The decision to refeed is currently made without any clinical or biological marker of the quality of pharyngeal suture healing. The idea of this study is that good initial healing (evidenced by low levels of inflammatory cytokine in drainage fluids) allows early refeeding without putting the patient at additional risk.
Main hypothesis and research objectives Main hypothesis: the determination of cytokines in postoperative drainage fluids (FODP) could be a tool for screening patients at no risk of developing a fistula, and for whom early refeeding (as early as postoperative day 3) could be proposed without exposing the patient to an additional risk of developing a FODP.
Read more
Study objectives Primary objective: to compare the rate of post-(pharyngo)-total laryngectomy fistula between an early refeeding strategy (3rd or 4th postoperative day) and a late refeeding strategy (current standard of care: 7th postoperative day) in a low-risk fistula group defined according to the level of inflammatory cytokines in drainage fluids on the second postoperative day.
Secondary objectives
To compare an early versus a late refeeding strategy for patients at low risk of fistula defined according to the level of inflammatory cytokines in drainage fluids on the second postoperative day for:
- length of hospital stay,
- evolution of nutritional status,
- time to postoperative radio-chemotherapy, if indicated postoperatively,
- improvement in quality of life,
- post-operative complications other than pharyngeal fistula. Evaluation of different strategies left to the investigator\'s choice (continuation of antibiotic therapy, increased delay before resumption of feeding, early resumption of surgery) in the group of patients at high risk of fistula, based on the determination of postoperative cytokines in drainage fluids.
Primary endpoint: Pharyngo-cutaneous fistula occurring within 30 days post-operatively (yes/no).
Number of subjects: 250 Inclusion criteria Major cancer patient justifying scheduled total laryngectomy or pharyngo-laryngectomy after multidisciplinary consultation.
Holder of a social security plan. Non-inclusion criteria Pregnant and breast-feeding women Persons under curatorship, guardianship, safeguard of justice or deprived of liberty.
Any medical condition deemed incompatible with the study by the investigator. Refusal to participate. Body mass index less than 18.5 kg/m2
Read the detailed description
Course of the study Patients will be recruited from the ENT departments of the Clermont Ferrand, Saint-Etienne, Lyon and Grenoble university hospitals, the Lyon (Centre Léon Bérard) and Paris (Institut Gustave Roussy) cancer centers, and the Le Puy En Velay and Valence hospitals, all of which are accredited for cervico-facial carcinology.
A multidisciplinary consultation meeting will be required to validate the surgical procedure.
Patients will be informed of the study by the investigating physician. After a period of reflection and a chance to answer any questions, the patient will be included in the study after consent has been obtained from an investigator.
The main risk factors for the development of a fistula will be recorded pre- and intraoperatively.
Surgical criteria will be common to all investigating teams. The most important of these will be the positioning of the LDPO collection drain opposite the pharyngeal closure site. The drain may or may not be aspirative, depending on local habits. The concomitant insertion of a phonatory prosthesis or a salivary bypass are not grounds for exclusion.
Post-operative care must meet precise specifications. Drainage fluids will be collected from the drainage bottle on D2 post-op. To do this, the entire drainage bottle will be recovered, and a new bottle will be placed over the drain if the drain is retained.
The liquid contained in the drainage bottle is then sterile-separated into different samples directly in the patient\'s hospital ward:
- Immunological sampling. A BD Falcon™ Conical Tubes 50 mL will be sent to the immunology laboratory associated with the investigating center (Clermont-Ferrand University Hospital Immunology Laboratory for the Clermont-Fd and Le Puy en Velay sites, Lyon University Hospital Immunology Laboratory for the Grenoble, Lyon, Valence and Lyon anti-cancer center, the immunology laboratory of the Assistance Publique Hopitaux de Paris for the Gustave Roussy Institute and the immunology laboratory for the Saint-Etienne center). The sample is then centrifuged at 3,000 rpm for 10 minutes at 4°C.a "high-risk" group for CPE.
- Bacteriological sampling. This sample will be sent rapidly to the bacteriology laboratory of the investigating center for standard cyto-bacteriological analysis.
For an IL 10 level on D2 post-op of less than 72pg/mL (so-called low-risk fistula group defined from the DEFILAC pilot study), two groups of patients will be constituted:
Low-risk fistula group: OPT performed on D3 or D4 (before randomization and after IL-10 results). If TPO classified according to van la Parra ≤1, patients will be randomized into 2 groups:
- "EARLY" group: Resumption of feeding on postoperative day 3 or 4 with a liquid or mixed diet.
- "TARDIF" group: return to a mixed diet from day 7 post-op. Randomization will be centralized, computerized with random block sizes, stratified by center and patient age.
If the TOP shows images classified according to van la Parra\>1, patients will join the so-called high-risk CPE exploratory arm.
If IL10 levels on D2 post-op exceed 72 pg/mL (high-risk group for post-op fistula), these patients will form a third, exploratory group, whose management will be left to the investigator\'s choice, with 3 possibilities (no change in investigators\' habits): repeat surgery to clean the surgical site and repair the pharyngeal sutures, broad-spectrum antibiotic therapy while awaiting the bacteriological results of the cytobacteriological examination of the drainage fluid on postoperative day 2, without repeat surgery, monitoring and no change in the investigator\'s routine.
Postoperative complications will then be noted and classified according to the Clavien-Dindo classification over a period of 30 postoperative days.
The appearance of a salivary fistula at the tracheostoma will be objectified by the appearance of saliva in the tracheostoma. The appearance of a fistula at the cervical level will be sought either by imaging methods in the event of a cervical complication (infection, hemorrhage) if no surgical revision is decided and surgically by loss of sealing confirmed surgically if a revision is necessary.
The appearance of a subsequent fistula will be noted. The patient will have a final consultation 30 days after surgery if he or she is no longer hospitalized.
The quality of life of the patients will be assessed throughout the study by completing an anxiety questionnaire and a depression questionnaire. This assessment will be done before surgery, on D5, D15 and D30 of surgery. Before surgery and at D5, these questionnaires will be completed during hospitalization. At D15 and D30, the questionnaires will be completed during hospitalization if the patient is still hospitalized or by mail if the patient has been discharged from the surgical department having performed the pharyngolaryngectomy procedure. The date of the start of chemoradiotherapy will then be noted and the time between surgery and the start of this treatment will be noted.
- Conditions
- Cancer, Otorhinolaryngeal
- Being tested
- early feeding resumption, late feeding resumption
- Keywords
- total laryngectomy
- Medical subject headings
- Otorhinolaryngologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
early feeding resumptionBehavioural
Resumption of food on the 3rd or 4th day post-operatively with a mixed diet.
late feeding resumptionBehavioural
Resumption of food on the 7th day post-operatively with a mixed diet.
| Study group | Role | What they receive |
|---|---|---|
| Early group | Experimental | For an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet. Receives: Behavioral: early feeding resumption |
| late group | Placebo comparator | For an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet. Receives: Behavioral: late feeding resumption |
| No intervention | No intervention | For an IL 10 level on postoperative day 2 greater than 72 pg/mL (group at high risk of postoperative fistula), these patients will constitute a third, exploratory group, whose management will be left to the investigator's discretion. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharyngocutaneous fistula occurring within 30 days postoperatively
Apparition or not of Pharyngocutaneous fistula occurring within 30 days postoperatively (yes/no).
Measured: Day 30
Secondary outcomes (23)
Hospitalization time in days.
Duration of Hospitalization time in days.
Measured: Day 30
Evolution of Weight in kg
Evolution of nutritional status between the start and the end of hospitalization assessed by the evolution of weight, strength of the forearm (Hand grip strength test)
Measured: Day 30
Nutrition Risk INdex
Evolution of nutritional status between the start and the end of hospitalization assessed by the evolution of the Nutrition Risk Index (NRI),
Measured: Day 30
Measure of grip strenght
Evolution of nutritional status between the start and the end of hospitalization assessed by the evolution of the grip strength of the forearm (Hand grip strength test)
Measured: Day 30
Deadlines for the implementation of post-operative radio-chemotherapy
Deadlines for the implementation of post-operative radio-chemotherapy
Measured: Day 30
Clavien-Dindo Classification
Surgical complications within 30 days post-operatively by the Clavien-Dindo classification
Measured: Day 30
Beck Depression Inventory II questionnaire
Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire
Measured: Day 0
Beck Depression Inventory II questionnaire
Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire
Measured: Day 5
Beck Depression Inventory II questionnaire
Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire
Measured: Day 15
Beck Depression Inventory II questionnaire
Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire
Measured: Day 30
Beck Anxiety Inventory
Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire
Measured: Day 0
Beck Anxiety Inventory
Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire
Measured: Day 5
Beck Anxiety Inventory
Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire
Measured: Day 15
Beck Anxiety Inventory
Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire
Measured: Day 30
EORTC-QLQ30 questionnaire
Measure of quality of life by EORTC-QLQ30 questionnaire
Measured: Day 0
EORTC-QLQ30 questionnaire
Measure of quality of life by EORTC-QLQ30 questionnaire
Measured: Day 5
EORTC-QLQ30 questionnaire
Measure of quality of life by EORTC-QLQ30 questionnaire
Measured: Day 15
EORTC-QLQ30 questionnaire
Measure of quality of life by EORTC-QLQ30 questionnaire
Measured: Day 30
Tumor status
Tumor status by TNM classification 8th edition
Measured: Day 30
Cytobacteriological examination of the drainage fluid.
Cytobacteriological examination of the drainage fluid.
Measured: Day 2
continuation of antibiotic therapy
continuation of antibiotic therapy (in days)
Measured: Day 30
Resuming food
increase in time before resuming food
Measured: Day 30
Surgical resumption
early surgical resumption and type of procedure performed in the group of patients with no intervention
Measured: Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start12 Feb 2025
- Primary completionMay 2028 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer, OtorhinolaryngealStudies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nicolas Saroul, Principal investigator, University Hospital, Clermont-Ferrand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06604494
- Sponsor's protocol ID
- PHRCI 2022 SAROUL
- Other IDs
- 2024-A00652-45
- Acronym
- RADEFILAC
- Status last verified
- Mar 2025
- First submitted
- 17 Sep 2024
- Last updated
- 22 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rehabilitation Improved by Early Detection of Fisyulas Post (Pharyngo) -Total Laryngectomy by Cytokine Measurement on Drainage Fluid on the Second Post-Operative Day
- ClinicalTrials.gov ID
- NCT06604494
- Acronym / sponsor ID
- RADEFILAC / PHRCI 2022 SAROUL
- Conditions
- Cancer, Otorhinolaryngeal
- Keywords
- total laryngectomy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- 12 Feb 2025 (actual)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2028 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Post-pharyngo-laryngectomy fistula is a frequent surgical complication, resulting in delayed patient management and reduced quality of life. A recent study has shown that the appearance of a fistula can be detected early by measuring cytokines (particularly IL10) in postoperative drainage fluids. Resumption of feeding following this surgery varies between postoperative day 5 and postoperative day 15, depending on the team\'s habits. Early refeeding reduces the length of hospital stay and improves patients\' quality of life. The decision to refeed is currently made without any clinical or biological marker of the quality of pharyngeal suture healing. The idea of this study is that good initial healing (evidenced by low levels of inflammatory cytokine in drainage fluids) allows early refeeding without putting the patient at additional risk.
Main hypothesis and research objectives Main hypothesis: the determination of cytokines in postoperative drainage fluids (FODP) could be a tool for screening patients at no risk of developing a fistula, and for whom early refeeding (as early as postoperative day 3) could be proposed without exposing the patient to an additional risk of developing a FODP.
Study objectives Primary objective: to compare the rate of post-(pharyngo)-total laryngectomy fistula between an early refeeding strategy (3rd or 4th postoperative day) and a late refeeding strategy (current standard of care: 7th postoperative day) in a low-risk fistula group defined according to the level of inflammatory cytokines in drainage fluids on the second postoperative day.
Secondary objectives
To compare an early versus a late refeeding strategy for patients at low risk of fistula defined according to the level of inflammatory cytokines in drainage fluids on the second postoperative day for:
- length of hospital stay,
- evolution of nutritional status,
- time to postoperative radio-chemotherapy, if indicated postoperatively,
- improvement in quality of life,
- post-operative complications other than pharyngeal fistula. Evaluation of different strategies left to the investigator\'s choice (continuation of antibiotic therapy, increased delay before resumption of feeding, early resumption of surgery) in the group of patients at high risk of fistula, based on the determination of postoperative cytokines in drainage fluids.
Primary endpoint: Pharyngo-cutaneous fistula occurring within 30 days post-operatively (yes/no).
Number of subjects: 250 Inclusion criteria Major cancer patient justifying scheduled total laryngectomy or pharyngo-laryngectomy after multidisciplinary consultation.
Holder of a social security plan. Non-inclusion criteria Pregnant and breast-feeding women Persons under curatorship, guardianship, safeguard of justice or deprived of liberty.
Any medical condition deemed incompatible with the study by the investigator. Refusal to participate. Body mass index less than 18.5 kg/m2
Detailed description
Course of the study Patients will be recruited from the ENT departments of the Clermont Ferrand, Saint-Etienne, Lyon and Grenoble university hospitals, the Lyon (Centre Léon Bérard) and Paris (Institut Gustave Roussy) cancer centers, and the Le Puy En Velay and Valence hospitals, all of which are accredited for cervico-facial carcinology.
A multidisciplinary consultation meeting will be required to validate the surgical procedure.
Patients will be informed of the study by the investigating physician. After a period of reflection and a chance to answer any questions, the patient will be included in the study after consent has been obtained from an investigator.
The main risk factors for the development of a fistula will be recorded pre- and intraoperatively.
Surgical criteria will be common to all investigating teams. The most important of these will be the positioning of the LDPO collection drain opposite the pharyngeal closure site. The drain may or may not be aspirative, depending on local habits. The concomitant insertion of a phonatory prosthesis or a salivary bypass are not grounds for exclusion.
Post-operative care must meet precise specifications. Drainage fluids will be collected from the drainage bottle on D2 post-op. To do this, the entire drainage bottle will be recovered, and a new bottle will be placed over the drain if the drain is retained.
The liquid contained in the drainage bottle is then sterile-separated into different samples directly in the patient\'s hospital ward:
- Immunological sampling. A BD Falcon™ Conical Tubes 50 mL will be sent to the immunology laboratory associated with the investigating center (Clermont-Ferrand University Hospital Immunology Laboratory for the Clermont-Fd and Le Puy en Velay sites, Lyon University Hospital Immunology Laboratory for the Grenoble, Lyon, Valence and Lyon anti-cancer center, the immunology laboratory of the Assistance Publique Hopitaux de Paris for the Gustave Roussy Institute and the immunology laboratory for the Saint-Etienne center). The sample is then centrifuged at 3,000 rpm for 10 minutes at 4°C.a "high-risk" group for CPE.
- Bacteriological sampling. This sample will be sent rapidly to the bacteriology laboratory of the investigating center for standard cyto-bacteriological analysis.
For an IL 10 level on D2 post-op of less than 72pg/mL (so-called low-risk fistula group defined from the DEFILAC pilot study), two groups of patients will be constituted:
Low-risk fistula group: OPT performed on D3 or D4 (before randomization and after IL-10 results). If TPO classified according to van la Parra ≤1, patients will be randomized into 2 groups:
- "EARLY" group: Resumption of feeding on postoperative day 3 or 4 with a liquid or mixed diet.
- "TARDIF" group: return to a mixed diet from day 7 post-op. Randomization will be centralized, computerized with random block sizes, stratified by center and patient age.
If the TOP shows images classified according to van la Parra\>1, patients will join the so-called high-risk CPE exploratory arm.
If IL10 levels on D2 post-op exceed 72 pg/mL (high-risk group for post-op fistula), these patients will form a third, exploratory group, whose management will be left to the investigator\'s choice, with 3 possibilities (no change in investigators\' habits): repeat surgery to clean the surgical site and repair the pharyngeal sutures, broad-spectrum antibiotic therapy while awaiting the bacteriological results of the cytobacteriological examination of the drainage fluid on postoperative day 2, without repeat surgery, monitoring and no change in the investigator\'s routine.
Postoperative complications will then be noted and classified according to the Clavien-Dindo classification over a period of 30 postoperative days.
The appearance of a salivary fistula at the tracheostoma will be objectified by the appearance of saliva in the tracheostoma. The appearance of a fistula at the cervical level will be sought either by imaging methods in the event of a cervical complication (infection, hemorrhage) if no surgical revision is decided and surgically by loss of sealing confirmed surgically if a revision is necessary.
The appearance of a subsequent fistula will be noted. The patient will have a final consultation 30 days after surgery if he or she is no longer hospitalized.
The quality of life of the patients will be assessed throughout the study by completing an anxiety questionnaire and a depression questionnaire. This assessment will be done before surgery, on D5, D15 and D30 of surgery. Before surgery and at D5, these questionnaires will be completed during hospitalization. At D15 and D30, the questionnaires will be completed during hospitalization if the patient is still hospitalized or by mail if the patient has been discharged from the surgical department having performed the pharyngolaryngectomy procedure. The date of the start of chemoradiotherapy will then be noted and the time between surgery and the start of this treatment will be noted.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Early group | Experimental | Behavioral: early feeding resumptionFor an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet. |
| late group | Placebo comparator | Behavioral: late feeding resumptionFor an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet. |
| No intervention | No intervention | –For an IL 10 level on postoperative day 2 greater than 72 pg/mL (group at high risk of postoperative fistula), these patients will constitute a third, exploratory group, whose management will be left to the investigator's discretion. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adult patient with cancer requiring a total laryngectomy or pharyngolaryngectomy scheduled after multidisciplinary consultation.
- Holder of a social security scheme
Key exclusion criteria (2 listed)
- Pregnant and breastfeeding women Persons under curatorship, guardianship, legal protection or deprived of liberty Any medical condition deemed by the investigator to be incompatible with the study. Refusal to participate. Body mass index less than 18.5 kg/ m2
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| early feeding resumptionResumption of food on the 3rd or 4th day post-operatively with a mixed diet. | Behavioural | Early group |
| late feeding resumptionResumption of food on the 7th day post-operatively with a mixed diet. | Behavioural | late group |
Primary outcome
Pharyngocutaneous fistula occurring within 30 days postoperatively
Time frame: Day 30
Apparition or not of Pharyngocutaneous fistula occurring within 30 days postoperatively (yes/no).
23 secondary outcomes
Hospitalization time in days.
Time frame: Day 30
Evolution of Weight in kg
Time frame: Day 30
Nutrition Risk INdex
Time frame: Day 30
Measure of grip strenght
Time frame: Day 30
Deadlines for the implementation of post-operative radio-chemotherapy
Time frame: Day 30
Clavien-Dindo Classification
Time frame: Day 30
Beck Depression Inventory II questionnaire
Time frame: Day 0
Beck Depression Inventory II questionnaire
Time frame: Day 5
Beck Depression Inventory II questionnaire
Time frame: Day 15
Beck Depression Inventory II questionnaire
Time frame: Day 30
Beck Anxiety Inventory
Time frame: Day 0
Beck Anxiety Inventory
Time frame: Day 5
Beck Anxiety Inventory
Time frame: Day 15
Beck Anxiety Inventory
Time frame: Day 30
EORTC-QLQ30 questionnaire
Time frame: Day 0
EORTC-QLQ30 questionnaire
Time frame: Day 5
EORTC-QLQ30 questionnaire
Time frame: Day 15
EORTC-QLQ30 questionnaire
Time frame: Day 30
Tumor status
Time frame: Day 30
Cytobacteriological examination of the drainage fluid.
Time frame: Day 2
continuation of antibiotic therapy
Time frame: Day 30
Resuming food
Time frame: Day 30
Surgical resumption
Time frame: Day 30
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nicolas Saroul principal investigator
University Hospital, Clermont-Ferrand
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing early feeding resumption and late feeding resumption in people with Cancer, Otorhinolaryngeal, run by University Hospital, Clermont-Ferrand at 7 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lise Laclautre (334.73.754.963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharyngocutaneous fistula occurring within 30 days postoperatively (time frame: Day 30). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025.